Researchers speculate that 32-134D changes the expression of a large number of genes, leading to significant changes in the tumor immune microenvironmen, and the percentage of CD8+T cells and natural killer cells, thus significantly enhancing anti PD1 therapy (153). This evidence concerns the gene CD8A and neoplasm.